With a team of 70 scientists from 22 different nations we turn cancer defects into novel treatments. Subscribe to our newsletter to stay updated about our research!
“Our commitment doesn’t stop with with science at the basics; we bring it all the way to the patients.
We improve Science, Health and Society”
The Helleday Laboratory consists of a large team of mixed professions; basic molecular biologists, medicinal chemists from industry and academia, pharmacologists, biochemists and practising clinicians, amongst others.
What brings us together is our dedication to make our basic science discoveries reach all the way to helping patients stay healthy and with their loved ones!
The Helleday Laboratory focuses on metabolism and DNA repair.
Nobel Prize laureate Otto Warburg pioneered cancer metabolism and coined that “The cure of human cancer will be the resultant of biochemistry of cancer and of biochemistry of man“. We think he was right, and with the molecular knowledge of altered metabolic pathways in cancer of today we can make real advances in progressing treatments. Read about how we target glucose metabolism or nucleotide metabolism.
Chemo- and radiotherapy is still the backbone of cancer treatments today and work by causing DNA damage. We know today that cancer cells have high load of DNA damage as compared to normal cells. Read about DNA damage and repair in cancer. Previously, the Helleday lab has exploited this and shown that PARP inhibitors selectively kill recombination defective cancers, such as inherited breast- and ovarian cancer. This is now approved treatment and help patients across the world.
“I am naturally happy and impressed by your work. Words can not describe how grateful I am; not only for my sake but for my children and family as well. It gives me hope to break the chain of cancer in the family. I hope for the drug to reach the market soon so more can be treated.” Translated from SwedishMarie
Many diseases have alterations in metabolic pathways often leading to DNA damage that manifest or define the disease. Our strategy is to identify basic mechanisms of proteins involved in metabolism and DNA repair to gain better understanding in disease and also develop small molecule inhibitors to selectively targeting these proteins as potential therapeutics. We reach our goal through open innovation and through a foundation, securing the future for our science and ensuring long term benefit to mankind.
We turn cancer defects into novel treatments. Cancer cells already have altered metabolic activity and a lot of DNA damage. With specific metabolic or DNA repair inhibitors we force the cancer cell into a trap where they cannot cope with the overload of DNA damage, without harming healthy cells with normal metabolic pathways.